Background: PAX-2 is expressed positive in normal endometrium, gets decreased in endometrial hyperplasia and becomes absent in endometrial carcinoma. PAX2 gene expression reduces in intensity from proliferative endometrium to nonatypical hyperplasia to atypical hyperplasia. Present study was aimed to study the expression of PAX2 in the diagnosis of premalignant and malignant lesions of endometrium. Material and Methods: Present study was single-center, cross sectional study, conducted in endometrial curettings and hysterectomy resection specimens diagnosed as Endometrial hyperplasia and Endometrial carcinoma.Representative sections were selected for PAX-2 immunohistochemistry (IHC). IHC was performed using polymer kit as per standard protocol. Results: The mean age of women in our study was 51.13 ± 10.51 years.Among 62 cases, 30 Endometrial Carcinoma and 32 Endometrial Hyperplasia (9 were Atypical Hyperplasia, 23 were Non-Atypical Hyperplasia).Out of the 30 Endometrial carcinoma cases, Endometrioid carcinoma is the most common (80%). The most common FIGO Stage was Stage IB (63%). Among the 30 cases of Endometrial Carcinoma, 25 (83%) showed complete loss of PAX2, while 5 (17%) showed partial loss.There is positive association between premalignant and malignant lesions with PAX2 loss. There is positive association between PAX2 loss and AUBand PMB (p – 0.001). Conclusion: Decrease in PAX2 expression was significantly associated with progression to endometrial carcinoma. Our study showed significant statistical difference in the PAX2 expression between the premalignant and malignant lesions of endometrium.